Steven Samuels, MD
Internal Medicine · Greenwood, INNPI 1205806387
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Bayer at 41.4% of the total. Reporting peaked in 2022 at $25,116 and has fallen 85.0% since, to $3,762 in 2025. Among internal medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,693 payments — averaging $42.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$30K
- GSK$13K
- AstraZeneca$9K
- AbbVie$3K
- Amgen$2K
- Johnson & Johnson$1K
- plus $12K from 54 others
What the payments were for
- Consulting fees$12,71418%
- Speaking & faculty fees$35,10649%
- Travel & lodging$1,5662%
- Food & beverage$22,61531%
- Education$2830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$72,283 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 416 | $665,986 |
| EliquisApixaban | 246 | $327,901 |
| JardianceEmpagliflozin | 235 | $315,027 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 230 | $276,865 |
| OzempicSemaglutide | 97 | $187,062 |
| XareltoRivaroxaban | 121 | $154,777 |
| FarxigaDapagliflozin Propanediol | 90 | $121,981 |
| MyrbetriqMirabegron | 86 | $88,297 |
| TrulicityDulaglutide | 55 | $69,421 |
| TradjentaLinagliptin | 37 | $50,519 |
| Breo ElliptaFluticasone/Vilanterol | 61 | $45,473 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $41,470 |
| LinzessLinaclotide | 50 | $39,417 |
| GemtesaVibegron | 30 | $38,912 |
| JanuviaSitagliptin Phosphate | 25 | $36,279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,024 | $735,407471 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $1,116 | $380,056285 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $13,352 | $363,809326 claims |
| PfizerEliquis | $1,208 | $327,901246 claims |
| Novo NordiskOzempic | $1,099 | $187,06297 claims |
| Johnson & JohnsonXarelto | $1,447 | $154,777121 claims |
| AstraZenecaFarxiga, Symbicort | $9,428 | $129,226103 claims |
| AbbVieLinzess, Creon, Ubrelvy | $3,017 | $90,11681 claims |
| Astellas Pharma US IncMyrbetriq | $161 | $88,29786 claims |
| MerckJanuvia, Janumet | $447 | $64,80945 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $117 | $38,91230 claims |
| BayerKerendia | $29,950 | $34,40119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Greenwood
- Abhinav SinghGreenwood$733K
- Todd DudleyGreenwood$63K
- Athanasios ThomaidesGreenwood$57K
- Girish KunapareddyTerre Haute$329K
- Raj VuppalanchiIndianapolis$279K
- Joseph Arulandula Porte$251K
- Napoleon MamintaIndianapolis$116K
- Jennifer PaisleyLawrenceburg$112K
- Allon FriedmanIndianapolis$111K
- John AyresIndianapolis$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.